Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation

Experimental Cell Research

Volumn 244, Issue 1, 1998, Pages 54-60

  An, Won G ^a   Chuman, Yutaka ^a   Fojo, Tito ^a   Blagosklonny, Mikhail V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

DNA damage; Mdm 2; p53; Proteasome; Protein stabilization

Indexed keywords

DNA; PROTEASOME; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; TRANSCRIPTION REGULATION;

EID: 0032505719     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1998.4193     Document Type: Article

References (43)

1. Maltzman, W., and Czyzyk, L. (1984). UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4, 1689-1694.
2. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311.
3. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597.
4. Fritsche, M., Haessler, C., and Brandner, G. (1993). Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8, 307-318.
5. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L., and Cho, K. R. (1993). Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA, 90, 3988-3992.
6. Graeber, T. G., Peterson, J. F., Tsai, M., Monica, K., Fornace, A. J., Jr., and Giaccia, A. J. (1994). Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14, 6264-6277.
7. An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., and Neckers, L. M. (1998). Stabilization of wild type p53 by hypoxia-inducible factor 1α. Nature 392, 405-408.
8. Linke, S. P., Clarkin, K. C., DiLeonardo, A., Tsou, A., and Wahl, G. M. (1996). A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10, 934-947.
9. Blagosklonny, M. V., Schulte, T. W., Nguyen, P., Mimnaugh, E. G., Trepel, J., and Neckers, L. (1995). Taxol induction of p21Waf1 and p53 requires c-raf-1. Cancer Res. 55, 4623-4626.
10. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W., and Galloway, D. A. (1996). Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2, 72-79.
11. Debernardis, D., Sire, E. G., De Feudis, P., Vikhanskaya, F., Valenti, M., Parodi, S., D'Incalci, M., and Broggini, M. (1997). p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res. 57, 870-874.
12. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.
13. Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M. (1993). The HPV16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505.
14. Chowdary, D. R., Dermody, J. J., Jha, K. K., and Ozer, H. L. (1994). Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol. 14, 1997-2003.
15. Ciechanover, A. (1994). The ubiquitin-proteasome proteolytic pathway. Cell 79, 13-21.
16. Maki, C. G., Huibregtse, J. M., and Howley, P. M. (1996). In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56, 2649-2654.
17. WAF1/CIP1 expression. Biochem. Biophys. Res. Commun. 227, 564-569.
18. Kubbutat, M. H., and Vousden, K. H. (1997). Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability. Mol. Cell. Biol. 17, 460-468.
19. Whitesell, L., Sutphin, P., An, W. G., Schulte, T., Blagosklonny, M. V., and Neckers, L. (1997). Geldanamycin-stimulated destabolization of mutated p53 is mediated by the proteasome in vivo. Oncogene 14, 2809-2816.
20. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated trans-activation. Cell 69, 1237-1245.
21. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
22. Kubbutat, M. H. G., Jones, S. N., and Vousden, K. H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
23. Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., and Kastan, M. B. (1997). DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11, 3471-3481.
24. Shieh, S. Y., Ikeda, M., Taya, Y., and Prives, C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334.
25. Mayo, L. D., Turchi, J. J., and Berberich, S. J. (1997). Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57, 5013-5016.
26. Blagosklonny, M. V., Toretskey, J., and Neckers, L. M. (1995). Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11, 933-939.
27. Wosikowski, K., Regis, J. T., Robey, R. W., Alvarez, M., Buters, J. T. M., Gudas, J. M., and Bates, S. E. (1996). Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ. 6, 1395-1403.
28. Giannakakou, P., Blagosklonny, M. V., and Fojo, T. (1998). Loss of p53 function precedes tubulin mutations in the development of paclitaxel (PTX) resistance. Proc. Am. Assoc. Cancer Res. 89, 1305.
29. Wu, G. S., and El-Deiry, W. S. (1996). p53 and chemosensitivity. Nat. Med. 2, 255-256.
30. Blagosklonny, M. V., Toretskey, J., Bohen, S., and Neckers, L. M. (1996). Conformation of mutated p53 requires functional HSP90. Proc. Natl. Acad. Sci USA 93, 8379-8383.
31. Halazonetis, T. D., Davis, L. J., and Kandil, A. N. (1993). Wild-type p53 adopts a "mutant"-like conformation when bound to DNA. EMBO J. 12, 1021-1028.
32. Cook, A. C., and Milner, J. (1990). Evidence for allosteric variants of wild-type p53, a tumour suppressor protein. Br. J. Cancer 61, 548-552.
33. Gannon, J. V., Greaves, R., Iggo, R., and Lane, D. P. (1990). Activating mutations in p53 produce a common conformational effect, a monoclonal antibody specific for the mutant form. EMBO J. 9, 1595-1602.
34. Blagosklonny, M. V., Wu, G. S., Somasundaram, K., and El-Deiry, W. S. (1997). Wild-type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells. Int. J. Oncol. 11, 1165-1170.
35. Lin, J. Y., Chen, J. D., Elenbaas, B., and Levine, A. J. (1994). Several hydrophobic amino acids in the p53 amino terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246.
36. Haupt, Y., Rowan, S., Shaulian, E., Vousden, K. H., and Oren, M. (1995). Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9, 2170-2183.
37. Medcalf, E. A., and Milner, J. (1993). Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation. Oncogene 8, 2847-2851.
38. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J. J., and Kohn, K. W. (1997). Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285-4301.
39. Blagosklonny, M. V. (1997). Loss of function and p53 stabilization. Oncogene 15, 1889-1893.
40. Blagosklonny, M. V., Iglesias, A., Zhan, Z., and Fojo, T. (1998). Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugs. Biochem. Biophys. Res. Comm. 244, 368-373.
41. Chang, Y.-C., Lee, Y.-S., Tejima, T., Tanaka, K., Omura, S., Heintz, N. H., Mitsui, Y., and Magae, J. (1998). mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9, 79-84.
42. Midgley, C. A., and Lane, D. P. (1997). p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15, 1179-1189.
43. Pritchard, D. M., Watson, A. J., Potten, C. S., Jackman, A. L., and Hickman, J. A. (1997). Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation. Proc. Natl. Acad. Sci. USA 94, 1795-1799.